Creative Biolabs has taken a significant step forward in the field of microbiome-based drug development by enhancing its Live Biotherapeutic Products (LBP) analytics. This move is set to provide a more standardized and controllable technical pathway from strain screening to product finalization, addressing a critical need in the industry for standardized analytical frameworks for safety, efficacy, and product consistency.
The company's platform integrates several critical elements of LBP development, including strain identification, contaminant analysis, formulation development, viability monitoring, and stability evaluation. These components are designed to tackle common bottlenecks in LBP development, such as the variability in functional capabilities of different microbial strains and the inherent vulnerability of live microbial formulations to contamination.
For strain validation, Creative Biolabs employs advanced techniques like 16S rRNA sequencing, MALDI-TOF mass spectrometry, and whole genome sequencing. These methods allow for the evaluation of immunomodulatory effects, adhesion potential, or antimicrobial actions of candidate strains, facilitating downstream efficacy research.
Contaminant detection and purity assessment are also key focuses of the platform, with screening for aerobic/anaerobic bacteria, yeast, and molds supported by CFU enumeration, qPCR, and digital PCR for strain-specific monitoring. Additionally, the platform aids in formulation science and stability studies, crucial for the development of biosimilar products, by assisting in cryoprotectant screening, enteric coat evaluation for capsules, and performing real-time or accelerated stability testing.
Beyond analytical services, Creative Biolabs has developed a portfolio of probiotic reference materials, including DNA standards, quality control strains, and engineered expression strains, to support methodological validation and testing reproducibility. The company's collection of probiotic strain products is particularly noteworthy, tailored for live probiotic research and industrial applications, supporting the engineering and recombinant expression of bioactive factors within probiotic hosts.
This advancement by Creative Biolabs represents a significant contribution to the scientific community's efforts to deepen the integration of biology and analytics in LBP development. Such platforms are expected to enhance predictability and control in this emerging therapeutic class, paving the way for more efficient and effective microbiome-based therapies.
